Kevin J. Mcnamara Sells 5,000 Shares of Chemed Corp. (CHE) Stock
Chemed Corp. (NYSE:CHE) CEO Kevin J. Mcnamara sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $232.59, for a total transaction of $1,162,950.00. Following the completion of the sale, the chief executive officer now directly owns 136,800 shares of the company’s stock, valued at approximately $31,818,312. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
Chemed Corp. (NYSE:CHE) opened at $231.61 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 0.48 and a current ratio of 0.50. The company has a market cap of $3,700.76, a P/E ratio of 28.55, a P/E/G ratio of 4.90 and a beta of 1.14. Chemed Corp. has a 52 week low of $145.35 and a 52 week high of $235.96.
Chemed Corp. (NYSE:CHE) last posted its quarterly earnings data on Thursday, October 26th. The company reported $2.15 EPS for the quarter, topping the consensus estimate of $2.00 by $0.15. The firm had revenue of $417.40 million during the quarter, compared to analyst estimates of $414.34 million. Chemed Corp. had a net margin of 4.62% and a return on equity of 27.69%. Chemed Corp.’s revenue was up 6.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.73 EPS. analysts forecast that Chemed Corp. will post 4.73 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 4th. Investors of record on Monday, November 13th will be paid a dividend of $0.28 per share. The ex-dividend date is Friday, November 10th. This represents a $1.12 annualized dividend and a dividend yield of 0.48%. Chemed Corp.’s dividend payout ratio (DPR) is presently 24.89%.
ILLEGAL ACTIVITY WARNING: “Kevin J. Mcnamara Sells 5,000 Shares of Chemed Corp. (CHE) Stock” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/18/kevin-j-mcnamara-sells-5000-shares-of-chemed-corp-che-stock.html.
Several hedge funds and other institutional investors have recently bought and sold shares of CHE. JPMorgan Chase & Co. raised its stake in shares of Chemed Corp. by 111.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 182,551 shares of the company’s stock worth $36,125,000 after acquiring an additional 96,237 shares in the last quarter. Voya Investment Management LLC raised its stake in shares of Chemed Corp. by 39.7% during the 2nd quarter. Voya Investment Management LLC now owns 214,764 shares of the company’s stock worth $43,926,000 after acquiring an additional 61,056 shares in the last quarter. Old Mutual Global Investors UK Ltd. raised its stake in shares of Chemed Corp. by 173.5% during the 3rd quarter. Old Mutual Global Investors UK Ltd. now owns 95,212 shares of the company’s stock worth $19,237,000 after acquiring an additional 60,399 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Chemed Corp. by 248.5% during the 2nd quarter. Renaissance Technologies LLC now owns 70,400 shares of the company’s stock worth $14,399,000 after acquiring an additional 50,200 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Chemed Corp. by 1.9% during the 2nd quarter. Vanguard Group Inc. now owns 1,830,711 shares of the company’s stock valued at $374,435,000 after purchasing an additional 34,938 shares in the last quarter. Hedge funds and other institutional investors own 96.58% of the company’s stock.
Several equities research analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Chemed Corp. from a “hold” rating to a “buy” rating and set a $251.00 price target for the company in a research report on Thursday, November 2nd. TheStreet raised shares of Chemed Corp. from a “c+” rating to an “a-” rating in a research report on Friday, October 27th. Royal Bank Of Canada upped their price target on shares of Chemed Corp. to $232.00 and gave the stock a “sector perform” rating in a research report on Tuesday, October 31st. KeyCorp reaffirmed a “hold” rating on shares of Chemed Corp. in a research report on Friday, October 27th. Finally, Oppenheimer Holdings, Inc. upped their price target on shares of Chemed Corp. from $220.00 to $225.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $236.00.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.